Bristol Myers Squibb ROE 2010-2022 | BMY

Current and historical return on equity (ROE) values for Bristol Myers Squibb (BMY) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
Bristol Myers Squibb ROE - Return on Equity Historical Data
Date TTM Net Income Shareholder's Equity Return on Equity
2022-03-31 $6.25B $31.65B 17.63%
2021-12-31 $6.99B $36.01B 18.92%
2021-09-30 $-5.41B $37.28B -14.44%
2021-06-30 $-5.08B $36.87B -12.49%
2021-03-31 $-6.22B $37.67B -14.22%
2020-12-31 $-9.02B $37.88B -19.26%
2020-09-30 $-0.04B $50.23B -0.09%
2020-06-30 $-0.56B $49.16B -1.34%
2020-03-31 $0.95B $49.98B 2.81%
2019-12-31 $3.44B $51.70B 13.63%
2019-09-30 $5.66B $17.75B 35.71%
2019-06-30 $6.20B $16.15B 41.81%
2019-03-31 $5.14B $15.32B 37.00%
2018-12-31 $4.92B $14.13B 36.99%
2018-09-30 $1.43B $13.75B 11.25%
2018-06-30 $0.38B $12.42B 2.89%
2018-03-31 $0.92B $12.91B 6.75%
2017-12-31 $1.01B $11.85B 7.18%
2017-09-30 $4.23B $14.91B 27.91%
2017-06-30 $4.59B $14.82B 29.84%
2017-03-31 $4.84B $14.54B 31.33%
2016-12-31 $4.46B $16.35B 28.87%
2016-09-30 $3.37B $15.78B 22.50%
2016-06-30 $2.87B $15.08B 19.35%
2016-03-31 $1.57B $14.55B 10.57%
2015-12-31 $1.57B $14.42B 10.32%
2015-09-30 $1.78B $15.27B 11.59%
2015-06-30 $1.79B $15.29B 11.71%
2015-03-31 $2.25B $15.69B 14.71%
2014-12-31 $2.00B $14.98B 13.12%
2014-09-30 $2.72B $15.20B 17.72%
2014-06-30 $2.69B $15.38B 17.67%
2014-03-31 $2.89B $15.53B 19.32%
2013-12-31 $2.56B $15.24B 17.67%
2013-09-30 $2.76B $14.71B 19.57%
2013-06-30 $1.36B $14.37B 9.77%
2013-03-31 $1.47B $13.70B 10.29%
2012-12-31 $1.96B $13.64B 13.15%
2012-09-30 $1.89B $13.90B 12.20%
2012-06-30 $3.56B $15.81B 22.14%
2012-03-31 $3.82B $16.25B 23.61%
2011-12-31 $3.70B $15.87B 23.01%
2011-09-30 $3.32B $16.44B 20.72%
2011-06-30 $3.30B $16.15B 20.80%
2011-03-31 $3.33B $15.90B 21.16%
2010-12-31 $3.09B $15.64B 19.84%
2010-09-30 $10.63B $15.86B 69.17%
2010-06-30 $10.64B $15.57B 71.00%
2010-03-31 $10.70B $15.23B 73.38%
2009-12-31 $10.59B $14.79B 75.37%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $163.597B $46.385B
Bristol-Myers Squibb is a one of the leading global specialty biopharmaceutical companies focused on the development of treatments targeting serious diseases like cancer, inflammatory, immunologic, cardiovascular or fibrotic diseases. Backed by its blockbuster immuno-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, comprising other drugs like Revlimid, Pomalyst, Sprycel, Yervoy and Empliciti. It also has important immunology and cardiovascular drugs like Orencia and Eliquis. It's experiencing growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program. After the sale of the global Diabetes business to AstraZeneca and the discontinuation of discovery research efforts in virology, it's focusing solely on research in core therapeutic areas like oncology, immuno-oncology, immunoscience, cardiovascular, fibrosis and genetically defined diseases. It acquried Celgene Corporation and MyoKardia. It received regulatory approvals for Reblozyl and Inrebic.
Stock Name Country Market Cap PE Ratio
Bio-Rad Laboratories (BIO.B) United States $14.907B 32.33
QIAGEN (QGEN) Netherlands $10.865B 17.15
Biohaven Pharmaceutical Holding (BHVN) United States $10.248B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.228B 0.00
Arcus Biosciences (RCUS) United States $1.901B 48.18
Emergent Biosolutions (EBS) United States $1.599B 6.85
Myovant Sciences (MYOV) United Kingdom $1.236B 0.00
Zymeworks (ZYME) Canada $0.320B 0.00
Gelesis Holdings (GLS) United States $0.114B 0.00
Enzo Biochem (ENZ) United States $0.104B 0.00
Ambrx Biopharma (AMAM) United States $0.103B 0.00
SQZ Biotechnologies (SQZ) United States $0.087B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00